Investors & Media
News
SAGE Therapeutics Announces Full Exercise of Over-Allotment Option
Including the exercise of the over-allotment, SAGE has sold a total of
5,750,000 shares of its common stock, which represents a total capital
raise of
J.P. Morgan and Goldman, Sachs & Co. are acting as joint book-running
managers for the offering. Leerink Swan is acting as lead manager and
A registration statement relating to these securities has been filed
with, and declared effective by, the
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
About SAGE Therapeutics
SAGE Therapeutics is a biopharmaceutical company committed to developing and commercializing novel medicines to treat life-threatening, rare CNS disorders. SAGE's lead program, SAGE-547, is in clinical development for super-refractory status epilepticus and is the first of several compounds the company is developing in its portfolio of potential seizure medicines. SAGE's proprietary chemistry platform has generated multiple new compounds that target GABAA and NMDA receptors, which are broadly accepted as impacting many psychiatric and neurological disorders. SAGE Therapeutics is a private company launched in 2010 by an experienced team of R&D leaders, CNS experts and investors. For more information, please visit www.sagerx.com.
Media Contact:
dan@purecommunicationsinc.com
973-271-6085
or
Investor
Contact:
monique@purecommunicationsinc.com
781-631-0759
Source: SAGE Therapeutics
News Provided by Acquire Media